Find relevant news articles from other European projects, below:


Browse our carefully curated library of the latest news and developments in all areas of immunotherapy here:


Looking to Novel Immunotherapeutics in Relapsed/Refractory Multiple Myeloma

Marc J. Braunstein, MD, PhD, discusses the evolution and promise of immunotherapeutics in multiple myeloma.

Visit website

Dr. Solomon on the Effects of Liso-Cel in Prior Anti-CD19 Therapy–Treated B-NHL

Scott R. Solomon, MD, discusses the effects of lisocabtagene maraleucel in patients with relapsed/refractory large B-cell non-Hodgkin lymphoma who were previously treated with CD19-directed therapies.

Visit website
Immunotherapy Web Featured Images 111

Can BiTE Molecules Make Off-the-Shelf Immuno-Oncology a Reality?

  Feb 18 2021 Tagged mAbs, BiTE, MM, NHL, LBCL

In hematologic malignancies, a new class of molecules is emerging that may ultimately offer clinical benefits comparable to those chimeric antigen receptor T-cell therapies while reducing some of the negatives associated with them.

Visit website

Key Takeaways from the First-in-Human Study of Odronextamab in B-cell NHL

  Feb 18 2021 Tagged mAbs, BiTE, NHL

Rajat Bannerji, MD, PhD, discussed key takeaways from the phase 1 study of the novel CD20xCD3 bispecific antibody, odronextamab in patients with highly refractory B-cell non-Hodgkin lymphoma.

Visit website
Immunotherapy Web Featured Images 110

CAR-T Meeting 2021 | CAR-T vs. BiTEs in B-cell malignancies

  Feb 18 2021 Tagged CAR-T, BiTE

Marion Subklewe, MD, LMU Hospital Munich, Munich, Germany, compares CAR T-cells to bispecific T-cell engagers (BiTEs). Firstly, Prof. Subklewe highlights that there are no randomized trials in any disease comparing CAR T-cells to BiTEs.

Visit website

HDP-101, an antibody-targeted amanitin conjugate to advance to phase I/IIa testi...

  Feb 17 2021 Tagged Abs, ADC, MM, anti-BCMA

The U.S. Food and Drug Administration (FDA) has announced that the B-cell maturation antigen (BCMA) antibody–drug conjugate HDP-101 can proceed to phase I/IIa testing.

Visit website
Immunotherapy Web Featured Images 107

Prof Robin Foà comments on NEJM paper “Dasatinib - Blinatumomab for Ph+ ALL in A...

Listen to Prof. Robin Foà commenting on the rationale and the results of a highly relevant paper published on the New England Journal of Medicine, and reporting an innovative “chemo-free” approach for Ph+ ALL patients.  Robin Foà, first author of the paper, highlights the main findings and scientific implications of a clinical trial involving 63 newly diagnosed adult patients with Philadelphia-positive (Ph+) acute lymphoblastic leukemia (ALL).

Read more
Immunotherapy Web Featured Images 101

AEMPS authorises Hospital Clínic's CAR-T ARI-0001 for patients with acute lympho...

The Spanish Agency of Medicines and Medical Devices (AEMPS) has approved CAR-T ARI-0001, developed by Hospital Clínic, as an advanced therapy drug of non-industrial production for its use in patients over 25 years of age with lymphoblastic leukaemia that is resistant to conventional treatments. It is the first CAR-T developed entirely in Europe to be approved by a regulatory agency.

Visit website
Immunotherapy Web Featured Images 90

T2EVOLVE: breakthrough alliance boosting Europe to the forefront of cancer immun...

T2EVOLVE is a new breakthrough alliance of academic and industry leaders in cancer immunotherapy under the European Union's Innovative Medicines Initiative (IMI). The key objective of T2EVOLVE is to accelerate development and increase awareness and access of cancer patients to immunotherapy with immune cells that harbor a genetically engineered T cell receptor (TCR) or synthetic chimeric antigen receptor (CAR). Simultaneously, T2EVOLVE aims to provide guidance on sustainable integration of these treatment into the EU healthcare system.

Visit website
Immunotherapy Web Featured Images 106

Keytruda Closer to Expanded EU Approval for Pediatric Resistant Hodgkin’s Lympho...

Keytruda (pembrolizumab) has been recommended for approval in the European Union (EU) to treat adults and children, 3 years and older, with relapsed or refractory classical Hodgkin’s lymphoma (cHL) whose disease failed to respond to autologous stem cell transplant (ASCT) or who received at least two prior therapies when ineligible for ASCT.

Visit website